Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gabriel Steg

Showing results (711-720 of 962) with videos related to

Pageof 97
Sort By:
Journal of the American College of Cardiology|October 8, 2021
Comparative Reductions in Investigator-Reported and Adjudicated Ischemic Events in REDUCE-ITPrakriti Gaba, Deepak L Bhatt, Robert P Giugliano, et al.
Circulation|October 28, 2021
Benefits of Icosapent Ethyl Across the Range of Kidney Function in Patients With Established Cardiovascular Disease or Diabetes: REDUCE-IT RENALArjun Majithia, Deepak L Bhatt, Allon N Friedman, et al.
Circulation. Cardiovascular Interventions|September 19, 2023
Complete Revascularization Versus Culprit-Lesion-Only PCI in STEMI Patients With Diabetes and Multivessel Coronary Artery Disease: Results From the COMPLETE TrialZardasht Oqab, Vijay Kunadian, David A Wood, et al.
JAMA Cardiology|September 27, 2019
Benefit and Risks of Aspirin in Addition to Ticagrelor in Acute Coronary Syndromes: A Post Hoc Analysis of the Randomized GLOBAL LEADERS TrialMariusz Tomaniak, Ply Chichareon, Yoshinobu Onuma, et al.
Lancet (London, England)|September 10, 2013
Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: a pooled analysis of patient-level dataPhilippe Gabriel Steg, Deepak L Bhatt, Christian W Hamm, et al.
Journal of the American College of Cardiology|April 28, 2022
Prevention of Cardiovascular Events and Mortality With Icosapent Ethyl in Patients With Prior Myocardial InfarctionPrakriti Gaba, Deepak L Bhatt, Ph Gabriel Steg, et al.
The New England Journal of Medicine|May 22, 2009
Early versus delayed invasive intervention in acute coronary syndromesShamir R Mehta, Christopher B Granger, William E Boden, et al.
European Heart Journal|October 25, 2011
Antiplatelet agents for the treatment and prevention of atherothrombosisCarlo Patrono, Felicita Andreotti, Harald Arnesen, et al.
Diabetes Care|January 2, 2015
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes and moderate or severe renal impairment: observations from the SAVOR-TIMI 53 TrialJacob A Udell, Deepak L Bhatt, Eugene Braunwald, et al.
European Heart Journal|December 8, 2019
Long-term ticagrelor for secondary prevention in patients with prior myocardial infarction and no history of coronary stenting: insights from PEGASUS-TIMI 54Remo H M Furtado, Jose C Nicolau, Giulia Magnani, et al.
Pageof 97

Showing results (711-720 of 962) with videos related to

Sort By:
Pageof 97
Journal of the American College of Cardiology|October 8, 2021
Comparative Reductions in Investigator-Reported and Adjudicated Ischemic Events in REDUCE-ITPrakriti Gaba, Deepak L Bhatt, Robert P Giugliano, et al.
Circulation|October 28, 2021
Benefits of Icosapent Ethyl Across the Range of Kidney Function in Patients With Established Cardiovascular Disease or Diabetes: REDUCE-IT RENALArjun Majithia, Deepak L Bhatt, Allon N Friedman, et al.
Circulation. Cardiovascular Interventions|September 19, 2023
Complete Revascularization Versus Culprit-Lesion-Only PCI in STEMI Patients With Diabetes and Multivessel Coronary Artery Disease: Results From the COMPLETE TrialZardasht Oqab, Vijay Kunadian, David A Wood, et al.
JAMA Cardiology|September 27, 2019
Benefit and Risks of Aspirin in Addition to Ticagrelor in Acute Coronary Syndromes: A Post Hoc Analysis of the Randomized GLOBAL LEADERS TrialMariusz Tomaniak, Ply Chichareon, Yoshinobu Onuma, et al.
Lancet (London, England)|September 10, 2013
Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: a pooled analysis of patient-level dataPhilippe Gabriel Steg, Deepak L Bhatt, Christian W Hamm, et al.
Journal of the American College of Cardiology|April 28, 2022
Prevention of Cardiovascular Events and Mortality With Icosapent Ethyl in Patients With Prior Myocardial InfarctionPrakriti Gaba, Deepak L Bhatt, Ph Gabriel Steg, et al.
The New England Journal of Medicine|May 22, 2009
Early versus delayed invasive intervention in acute coronary syndromesShamir R Mehta, Christopher B Granger, William E Boden, et al.
European Heart Journal|October 25, 2011
Antiplatelet agents for the treatment and prevention of atherothrombosisCarlo Patrono, Felicita Andreotti, Harald Arnesen, et al.
Diabetes Care|January 2, 2015
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes and moderate or severe renal impairment: observations from the SAVOR-TIMI 53 TrialJacob A Udell, Deepak L Bhatt, Eugene Braunwald, et al.
European Heart Journal|December 8, 2019
Long-term ticagrelor for secondary prevention in patients with prior myocardial infarction and no history of coronary stenting: insights from PEGASUS-TIMI 54Remo H M Furtado, Jose C Nicolau, Giulia Magnani, et al.
Pageof 97